about
Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.Eribulin mesylate in the treatment of metastatic breast cancerA phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate.Eribulin mesylate in patients with refractory cancers: a Phase I study.Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicinEribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.Anticancer drug discovery from the marine environment.Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.Eribulin: a novel cytotoxic chemotherapy agent.Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
P921
Q34031560-B37B20EC-8FCB-4AF2-9DD2-35BE912AA7A6Q35599745-3079A82F-DCE7-46C2-B796-F50B54CBD60AQ35633159-E8971000-C4C4-4B77-9894-9F6D5DE086CBQ35699382-38789C80-C01B-4803-A649-BEFDEC5F4C6CQ35783841-79091DEB-B59D-4A80-88CB-4F207637AF6CQ35872691-D06A0A93-EBED-47CD-B10D-574FF3A6CD2BQ36199963-3ECC2DD8-25AE-4255-B982-E9B6E566D1C3Q36205403-CEAFE8FA-CA04-4388-ABE3-E5BDA7B0D0A3Q36629243-98264A44-A99C-480B-A110-9D46AD83DF95Q37873164-73D7BBC9-1257-491D-A2AF-16CA693863DCQ37921490-0AD88525-AA28-486D-BA81-382CD39BC7E0Q37944440-CA1C1BBB-3EA3-4C49-BB4E-78539310B89FQ37973101-02A40F1B-2D28-4B8F-975B-AF1955997C11Q37979165-B8DEAF3D-5F1C-4F1D-B2D0-5667D101A272Q38012442-33312F2A-FD68-4EC8-BEBD-6FBA56089B57Q38022118-6D9ADAFD-26A8-42C2-83FF-9F0D8A15F29FQ38029266-B1804DA4-4052-441D-8619-2EEF87244008Q39346965-4E123252-523A-47C7-AD99-9CD4E3955CDBQ39775442-3F961ADA-0402-4867-B35D-0DE08B010F58Q42715686-ADDF8561-951A-468D-82FA-6D94385AD849Q43861920-09472918-FF3E-441A-8299-F253B1C233C6Q47628083-53737F0E-41D2-4301-82AD-39FE3C169362Q51533397-51C05DFF-1656-4FC1-A78A-0FB261E7354EQ58819336-09F2909B-6D80-4217-A369-898658CBC199
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Eribulin-Mesylat
@de
eribulin mesylate
@en
type
label
Eribulin-Mesylat
@de
eribulin mesylate
@en
prefLabel
Eribulin-Mesylat
@de
eribulin mesylate
@en
P592
P661
P662
P683
P2017
C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C ...... H]9OC)C[C@@H](CN)O.CS(=O)(=O)O
P2067
P2115
N0000182254
P231
441045-17-6
P232
P233
CC1CC2CCC3C(=C)CC(O3)CCC45CC6C ...... O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O
P234
1S/C40H59NO11.CH4O3S/c1-19-11- ...... 5+,36+,37+,38-,39+,40+;/m1./s1
P235
QAMYWGZHLCQOOJ-WRNBYXCMSA-N
P2566
100.244.966
P274
C₄₁H₆₃NO₁₄S
P2892
P3345
P592
CHEMBL1683544
P652
AV9U0660CW